1. FIRST‐MIND: A PHASE IB, OPEN‐LABEL, RANDOMIZED STUDY TO ASSESS SAFETY OF TAFASITAMAB OR TAFASITAMAB + LENALIDOMIDE IN ADDITION TO R‐CHOP IN PATIENTS WITH NEWLY DIAGNOSED DLBCL. (17th June 2021) Authors: Belada, D; Kopeckova, K; Bergua Burgues, J. M; André, M; Pérez Persona, E; Pichler, P; Klöpfer, P; Brackertz, B; Lohrmann, E; Lahiry, A; Shah, N; Brugger, W; Burke, J. M; Nowakowski, G. S Journal: Hematological oncology Issue: Volume 39(2021)Supplement 2 Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. POLATUZUMAB VEDOTIN PLUS BENDAMUSTINE AND RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA IN THE REAL WORLD. (17th June 2021) Authors: Vodicka, P; Benesova, K; Janikova, A; Prochazka, V; Belada, D; Mocikova, H; Steinerova, K; Duras, J; Karban, J; Hanackova, V; Sykorova, A; Obr, A; Trneny, M Journal: Hematological oncology Issue: Volume 39(2021)Supplement 2 Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗